February 17th, 2021 Comments Off on Management
Management
- Fb
- Tw
- Pin
Recent Posts
- Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline
- Agomab Receives FDA Fast Track Designation for AGMB-129 in Fibrostenosing Crohn’s Disease and Starts STENOVA Phase 2a Clinical Trial
- Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn’s Disease
- Agomab Therapeutics Selected as One of Fierce Biotech’s “Fierce 15” Companies of 2022
- Agomab Raises Additional $40.5 Million Through Series B Extension Bringing Total Amount to $114 Million
